Blue-light filtering IOLs

Article

Making driving safer in glare conditions

When driving in high-glare conditions the visibilities of objects are reduced, and lowcontrast objects may be rendered invisible. A major cause of the problems associated with glare is that light is scattered within the eye onto the retina (veiling glare) thus reducing the contrast of the retinal image. This reduction of contrast is called disability glare.

Study design

The main indicator of driving safety that was used was the safety margin at the point when the driver initiated the turn. This safety margin can be thought of as the amount of time that would be leftover if the driver made the turn: a safety margin of +2 seconds means that the driver could finish their turn and leave the intersection 2 seconds before the oncoming car entered the same intersection (a safe situation) while a safety margin of 0 seconds means the back bumper of the driver's car would clear the intersection at the exact instant the oncoming vehicles' front bumper entered the intersection (a very unsafe situation). A smaller safety margin in this context increases the likelihood of a collision with the oncoming vehicle. Of particular interest was whether the safety margin used by drivers for turns changed in the presence of glare and whether this change was effected by the used of blue-light filtering IOLs.

Across the two studies a total of 67 patients (mean age of 72 years) previously implanted with IOLs developed by Alcon Laboratories were evaluated. There were two blue light-filtering groups: 17 patients implanted with blue-light filtering, acrylic IOLs (AcrySof Model SA60AT) and 18 patients implanted with blue-light filtering, toric IOLs (AcrySof Models SN6ATT or SN60TT). The control groups (a total of 32 patients) were implanted with IOLs without UVonly filtering (AcrySof Model SA60AT).

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.